Printer Friendly

T CELL SCIENCES AWARDED U.S. PATENT FOR COMPLEMENT INHIBITOR; SCR1 IN CLINICAL TRIALS

 CAMBRIDGE, Mass., May 24 /PRNewswire/ -- T Cell Sciences (NASDAQ: TCEL), announced today that the U.S. Patent and Trademark office has issued a patent (#5,212,071) covering sCR1 (soluble complement receptor type 1). sCR1 is a genetically engineered version of a human protein that regulates the complement system, one of the body's first lines of defense against disease. sCR1 is currently undergoing initial clinical studies in burn patients at risk of developing adult respiratory distress syndrome.
 The complement system is a group of proteins that serves as a molecular scavenger, identifying, destroying and eliminating damaged tissue. However, in a number of clinical conditions, complement activation leads to an acute inflammatory response out of proportion to the initial injury. This excess activity can result in potentially life-threatening, secondary destruction of healthy tissue or tissue that might otherwise recover from the initial injury. sCR1 may be useful in limiting this inappropriate complement activity. The naturally occurring protein, called CR1, normally regulates complement activity.
 In animal studies, sCR1 has reduced tissue damage in models of adult respiratory distress syndrome, reperfusion injury following myocardial infarct, organ transplantation rejection, and cardiopulmonary bypass.
 "Inhibition of the complement system represents a unique approach to treating diseases resulting from inflammatory tissue damage," said Alan Tuck, president and chief executive officer of T Cell Sciences. "The patent affirms our strong proprietary position in this field. In addition to covering our lead compound, sCR1, the patent covers a number of other molecules we are evaluating as second generation compounds."
 The patent covers the nucleic acid sequence of CR1 and its fragments, recombinantly produced molecules and recombinant methods of producing CR1. T Cell Sciences is the exclusive licensee of all rights to this patent and has a collaborative agreement with SmithKline Beecham to develop, manufacture and market sCR1. The assignees on the patent are The John Hopkins University, Brigham & Women's Hospital, and T Cell Sciences. The inventors on the patent are Douglas Fearon, Lloyd Klickstein, Winnie Wong, Gerald Carson, Michael Concino, Stephen Ip and Savvas Makrides.
 Located in Cambridge, Mass., T Cell Sciences, Inc. is utilizing proprietary T cell and soluble receptor technology to develop pharmaceutical products to treat diseases of inflammation, autoimmunity and cancer. T Cell Diagnostics, an 84 percent owned subsidiary of T Cell Sciences, develops, manufactures and markets innovative diagnostic and research products.
 -0- 5/24/93 R
 /CONTACT: Alan W. Tuck, president and CEO, or Susan Primrose, manager, market development & communications, both of T Cell Sciences, 617-621-1400/
 (TCEL)


CO: T Cell Sciences, Inc. ST: Massachusetts IN: MTC SU:

DJ -- NE003R -- 1666 05/24/93 11:31 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 24, 1993
Words:431
Previous Article:UNIVERSAL PICTURES' 'HARD TARGET' SET TO OPEN NATIONWIDE ON AUG. 20
Next Article:BEVEL GRANITE COMPANY, INC. ANNOUNCES EXPANSION THROUGH MERGER WITH ROGAN GRANITINDUSTRIE'S MONUMENT BUSINESS
Topics:


Related Articles
T CELL SCIENCES BEGINS PHASE I CLINICAL TRIALS OF sCR1 in ARDS
T CELL SCIENCES BEGINS PHASE 1 CLINICAL TRIALS OF TP10 IN REPERFUSION INJURY FOLLOWING MYOCARDIAL INFARCTION
T CELL SCIENCES REPORTS PHASE I DATA ON TP10 (SCR1)
T CELL SCIENCES, INC. BEGINS PHASE IIA TRIAL OF TP10 FOR ADULT RESPIRATORY DISTRESS SYNDROME
Alexion Receives Issued Patent for Class of C5 Complement Inhibitors
Preliminary Phase I/II Study Results Demonstrate Clinical Efficacy Of T Cell Sciences' TP10 Complement Inhibitor In Lung Transplant Patients
Alexion Issued Patent Relating to Xenotransplant Program
Aegera adds six patents to their apoptosis patent estate.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters